<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <channel>
  <title>Daily CSR</title>
  <description><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></description>
  <link>https://www.dailycsr.com/</link>
  <language>us</language>
  <dc:date>2026-07-09T02:41:21+02:00</dc:date>
  <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="alternate" href="https://www.dailycsr.com/xml/atom.xml" type="text/xml" />
  <item>
   <guid isPermaLink="false">tag:https://www.dailycsr.com,2026:rss-96804576</guid>
   <title>HMS Vision Expands VR Cataract Surgery Training at WMU</title>
   <pubDate>Mon, 01 Jun 2026 16:56:00 +0200</pubDate>
   <dc:language>us</dc:language>
   <dc:creator>Debashish Mukherjee</dc:creator>
   <dc:subject><![CDATA[Companies]]></dc:subject>
   <description>
   <![CDATA[
        <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/96804576-67478162.jpg?v=1780326009" alt="HMS Vision Expands VR Cataract Surgery Training at WMU" title="HMS Vision Expands VR Cataract Surgery Training at WMU" />
     </div>
     <div>
      <div style="text-align: justify;">HMS Vision Inc. unveiled an expanded version of its Simulation-Based Eye Surgery Training Program at the Eye Hospital of Wenzhou Medical University (WMU) during Vision China 2026. Since the partnership was established in 2018, the initiative has experienced substantial growth. With the latest enhancement, WMU has become the world's largest user of the HelpMeSee virtual reality cataract surgery training platform. The upgraded facility now houses six award-winning HelpMeSee Eye Surgery Simulators, significantly increasing its capacity to train surgeons in Manual Small Incision Cataract Surgery (MSICS) and Phacoemulsification (Phaco), while strengthening ophthalmic education throughout China and the broader Asia-Pacific region. <br />   <br />  The expansion further deepens the collaboration between HMS Vision Inc., through its wholly owned subsidiary Beijing HMS Vision Technical Consulting Co. Ltd., and WMU. By combining WMU's clinical and academic expertise with a structured, instructor-guided, competency-based training framework, the partnership delivers a consistent and high-quality learning experience that aligns with global standards. The initiative also supports efforts to reduce the burden of cataract-related vision loss, which affects an estimated 17–20 million people across China. <br />   <br />  Leveraging advanced haptic virtual reality technology, the HelpMeSee training system provides a realistic and immersive environment where trainees can practice every stage of cataract procedures—including MSICS and Phaco—without exposing patients to risk. <br />   <br />  “This expansion marks a significant step forward in enhancing surgical training capabilities at Wenzhou Medical University,” said Prof. Dr. Xu Xu, Director of the Ophthalmic Surgical Skill Training Center. <br />   <br />  Assoc. Prof. Dr. Yuan Yimin, Director of Academic Affairs at the Eye Hospital of Wenzhou Medical University, emphasized the impact of the expansion, stating, “With six cutting-edge HelpMeSee Eye Surgery Simulators now available, we can train more surgeons through intensive simulation-based practice. This approach helps improve surgical proficiency, supports better patient outcomes, and addresses the increasing demand for cataract treatment both in China and internationally.” <br />   <br />  The enlarged training center is designed to accommodate large-scale, instructor-led cataract surgery programs. Participants can complete hundreds of simulated procedures within a condensed period, enabling them to develop technical skills, build confidence, and prepare more effectively for live surgical environments. The program also incorporates objective, data-driven performance assessments that complement traditional surgical education methods. <br />   <br />  As cataract-related blindness and visual impairment continue to affect millions worldwide, scalable and effective training solutions have become increasingly important. The expanded WMU facility is positioned as a key regional hub for developing highly skilled cataract surgeons capable of meeting growing healthcare demands. <br />   <br />  This achievement aligns with the broader objective of increasing access to cataract surgery training throughout Asia and other regions. By providing surgeons with the opportunity to refine their techniques in a safe, risk-free setting, the program contributes to reducing preventable blindness and expanding access to sight-restoring treatment. <br />   <br />  Through their continued partnership, HMS Vision Inc. and Wenzhou Medical University reaffirm their dedication to advancing innovation in surgical education and improving global eye health, further establishing WMU as a premier center for ophthalmic surgical training and excellence.</div>  
     </div>
     <br style="clear:both;"/>
   ]]>
   </description>
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/96804576-67478162.jpg</photo:imgsrc>
   <link>https://www.dailycsr.com/HMS-Vision-Expands-VR-Cataract-Surgery-Training-at-WMU_a5838.html</link>
  </item>

  <item>
   <guid isPermaLink="false">tag:https://www.dailycsr.com,2026:rss-95544793</guid>
   <title>Belief BioMed &amp; Grand Life Sciences Partner to Advance Hemophilia A Gene Therapy in China</title>
   <pubDate>Mon, 23 Mar 2026 07:24:00 +0100</pubDate>
   <dc:language>us</dc:language>
   <dc:creator>Debashish Mukherjee</dc:creator>
   <dc:subject><![CDATA[Companies]]></dc:subject>
   <description>
   <![CDATA[
        <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/95544793-66784885.jpg?v=1774247180" alt="Belief BioMed &amp; Grand Life Sciences Partner to Advance Hemophilia A Gene Therapy in China" title="Belief BioMed &amp; Grand Life Sciences Partner to Advance Hemophilia A Gene Therapy in China" />
     </div>
     <div>
      <div style="text-align: justify;">Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (“Grand Life Sciences”) have entered into an exclusive partnership agreement. As part of the deal, Belief BioMed will provide Grand Life Sciences with commercialization rights for its investigational therapy, BBM-H803, across Mainland China, Hong Kong, Macau, and Taiwan. <br />   <br />  This partnership reflects both companies’ commitment to combining their expertise and resources to speed up the product’s path to market, expand access to innovative treatments for patients with hemophilia A, and support the advancement of gene therapy. The agreement was formalized by Xiao Xiao, Co-founder, Chairman, and Chief Science Officer of Belief BioMed, and Zenghui Feng, Chairman of Grand Life Sciences. <br />   <br />  Dr. Xiao Xiao stated that Belief BioMed is dedicated to advancing gene therapy, with a pipeline addressing both rare and common diseases to meet significant unmet medical needs. He highlighted the company’s milestone in 2025 with the launch of China’s first gene therapy for hemophilia B, BBM-H901, which introduced a new treatment option for patients. Looking ahead to hemophilia A, he expressed enthusiasm for the collaboration, noting that Belief BioMed’s clinical development strengths, combined with Grand Life Sciences’ commercialization expertise, will help accelerate bringing new gene therapies to patients in China. <br />   <br />  Zenghui Feng emphasized that the partnership marks an important strategic step in strengthening Grand Life Sciences’ innovative portfolio. By leveraging the blood product resources of its subsidiary, Grand Shuyang, along with its deep experience in hematology, the company aims to work closely with Belief BioMed to advance hemophilia A treatment. He added that integrating advanced research capabilities with established commercialization infrastructure will help improve patient access more quickly, with the ultimate goal of reducing the burden of frequent treatments and minimizing the risks associated with bleeding episodes for patients.</div>  
     </div>
     <br style="clear:both;"/>
   ]]>
   </description>
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/95544793-66784885.jpg</photo:imgsrc>
   <link>https://www.dailycsr.com/Belief-BioMed-Grand-Life-Sciences-Partner-to-Advance-Hemophilia-A-Gene-Therapy-in-China_a5630.html</link>
  </item>

 </channel>
</rss>
